Paclitaxel is a taxane-class cytotoxic chemotherapeutic agent for cancer treatment.
Paclitaxel inhibits microtubule depolymerization in dividing cells, blocking the metaphase-anaphase transition and eventually leading to apoptosis. Lack of specificity for tissue type have made this drug a mainstay of treatment for a variety of malignancies, especially those of the ovary, breast, and lung, while also underlying its significant off-target toxicity.
Patients should be pre-treated with corticosteroids and anti-histamines due to a relatively high risk of severe hypersensitivity reactions during infusion.
- Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017 Nov 8. doi: 10.1093/nar/gkx1037
- Epocrates Rx Online [Internet database]. San Mateo (CA): Epocrates, Inc. 2003. Retrieved at mobile.epocrates.com. Web-based; continuous content updates. Accessed 2018 April 25.